Alzinova AB (OSTO:ALZ) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alzinova AB Debt-to-Equity?

Alzinova AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Alzinova AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.80 Mil. Alzinova AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr113.86 Mil. Alzinova AB's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alzinova AB's Debt-to-Equity or its related term are showing as below:

OSTO:ALZ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.03
Current: 0.01

During the past 8 years, the highest Debt-to-Equity Ratio of Alzinova AB was 0.03. The lowest was 0.01. And the median was 0.01.

OSTO:ALZ's Debt-to-Equity is ranked better than
99.91% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:ALZ: 0.01

Alzinova AB Debt-to-Equity Historical Data

The historical data trend for Alzinova AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB Debt-to-Equity Chart

Alzinova AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Alzinova AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	-	-	0.01

Competitive Comparison of Alzinova AB's Debt-to-Equity

For the Biotechnology subindustry, Alzinova AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzinova AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzinova AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alzinova AB's Debt-to-Equity falls into.

Alzinova AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alzinova AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.8)	/	113.858
	=	0.01

Alzinova AB's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.8)	/	113.858
	=	0.01

Alzinova AB (OSTO:ALZ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alzinova AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alzinova AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzinova AB (OSTO:ALZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

78D:Germany

Address

Pepparedsleden 1, Molndal, SWE, SE-431 83

Website

https://www.alzinova.com

Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB (OSTO:ALZ) Headlines

No Headlines